Table 2.
Genotypes frequency of donors’ CTLA-4 SNPs in relation to aGvHD presence
| Donors polymorphisms | aGvHD (+) | aGvHD (−) | OR | 95 % CI | ||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | |||||
|
CTLA-4c.49A>G (rs231775) |
AA | 54 | 32.10 | 47 | 35.10 | 1a | – | χ2
df=2 = 0.49 p = 0.78 |
| AG | 87 | 51.80 | 64 | 47.80 | 1.18 | 0.71–1.96 | ||
| GG | 27 | 16.10 | 23 | 17.20 | 1.02 | 0.52–2.02 | ||
| Σ | 168 | 100 % | 134 | 100 % | – | – | ||
| HWE | p = 0.43 | p = 0.86 | ||||||
| CT60G>A (rs3087243) |
GG | 69 | 41.10 | 47 | 35.30 | 1a | – | χ2
df=2 = 4.16 p = 0.13 |
| GA | 83 | 49.40 | 63 | 47.40 | 0.90 | 0.55–1.47 | ||
| AA | 16 | 9.50 | 23 | 17.30 | 0.48 | 0.23–1.00 | ||
| Σ | 168 | 100 % | 133 | 100 % | – | – | ||
| HWE | p = 0.23 | p = 0.86 | ||||||
aGvHD acute graft versus host disease, OR odds ratio, CI confidence interval, HWE Hardy-Weinberg equilibrium
aBaseline group